Clinical Trial Update: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial results update for Vyxeos (CPX-351) in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Vyxeos (CPX-351)

Snippet

Sponsor: Rondeep Brar | Conditions: Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7) | Phase 2 | Status: COMPLETED | Results posted: 2019-01-15